Use of low molecular weight heparin in cats: 57 cases (1999-2003)

J Am Vet Med Assoc. 2004 Oct 15;225(8):1237-41. doi: 10.2460/javma.2004.225.1237.

Abstract

Objective: To determine duration of administration, complications, and frequency of aortic thromboembolism associated with administration of low molecular weight heparin (dalteparin) in cats.

Design: Retrospective study.

Animals: 57 cats treated with dalteparin

Procedure: Data were recorded from the medical records of cats treated with dalteparin, and owners were contacted by telephone for information regarding ease of administration and possible adverse effects.

Results: Dalteparin was easily administered by owners. Median dose was 99 U/kg (45 U/lb) once or twice daily. Bleeding complications were infrequent. Of 43 cats with cardiomyopathy that received owner-administered dalteparin for a median follow-up time of 172 days, 8 cats developed documented or possible arterial thromboembolism.

Conclusions and clinical relevance: Dalteparin was easily administered by owners and was well tolerated by cats. Whether dalteparin administration can reduce the frequency or severity of arterial thromboembolism is not yet known.

MeSH terms

  • Animals
  • Anticoagulants / adverse effects
  • Anticoagulants / therapeutic use*
  • Blood Coagulation / drug effects
  • Cat Diseases / drug therapy*
  • Cats
  • Female
  • Heparin, Low-Molecular-Weight / adverse effects
  • Heparin, Low-Molecular-Weight / therapeutic use*
  • Injections, Subcutaneous / veterinary
  • Male
  • Retrospective Studies
  • Thromboembolism / drug therapy
  • Thromboembolism / veterinary*
  • Treatment Outcome

Substances

  • Anticoagulants
  • Heparin, Low-Molecular-Weight